Metastatic (secondary) breast cancer is the leading cause of breast cancer deaths. As we strive towards zero deaths from breast cancer, it’s our biggest research problem to solve.
By raising funds and hosting a Pink Ribbon Breakfast this October, you’re taking a stand against secondary breast cancer. You’re helping fund world-class research to find lasting solutions and ultimately - save lives.
Your support will fund urgent
research into…
 |
PREVENTION |
More research is needed to understand why, how and when breast cancer spreads. The more we understand, the more chances we have of preventing it.
 |
DETECTION |
More research is needed to develop effective tools to predict, detect and monitor the spread of cancer. The sooner we can detect it, the better we can treat it.
 |
TARGETED TREATMENTS |
More research is needed for personalised treatments for metastatic breast cancer. The more targeted the treatment strategy, the better the outcome.
The funds you raise are vital. The more you raise, the closer we get to zero deaths from breast cancer.
Could support researchers in the development of a new combination therapy that is more potent against metastatic breast cancer, while reducing harmful side-effects and heart damage.
Could support researchers to develop world-class diagnostic and imaging tools to see exactly where breast cancer has spread, as early as possible.
Could support researchers to develop a simple, non-invasive blood test to predict, detect and monitor the return and spread of breast cancer. This could lift the cloud of fear that so many breast cancer survivors live under.
WHERE YOUR MONEY GOES
When you support the National Breast Cancer Foundation (NBCF), you’re supporting targeted breast cancer research – research that is selected for its potential to reap tangible, game-changing results. NBCF has a number of groundbreaking research projects focusing on the prevention, detection and treatment of metastatic breast cancer. Here are just a few. With your help, we can fund more.
 |
ASSOCIATE PROFESSOR ALEXANDER SWARBRICKGarvan Institute of Medical Research NBCF-funded researcher Associate Professor Alexander Swarbrick is using cutting-edge technologies to study the genetics of cancer cells of women with triple negative breast cancer. He’s using ‘single cell genomics’ to analyse samples collected during chemotherapy as well as during metastatic stages of the disease. This exciting research may not only uncover the fundamental mechanisms controlling the response to chemotherapy, but may also provide remarkable new opportunities for predictive tests and drug targets for chemo-resistant triple negative breast cancer. |
 |
DR CHRISTINE CHAFFERGarvan Institute of Medical Research NBCF-funded researcher Dr Christine Chaffer is developing new techniques to stop aggressive cell populations from spreading. Doing so will prevent tumour progression, recurrence and metastasis. Dr Chaffer and her team discovered that by blocking a novel marker, the growth and spread of tumours in experimental models has been stopped. Her project will investigate the most effective methods of blocking the enzyme, which if effective, will provide a new therapeutic strategy to prevent metastasis, slow progression and improve outcomes for those affected by breast cancer. |
 |
DR DELPHINE MERINOLa Trobe University / Olivia Newton-John Cancer Research Institute Dr Merino and her team will investigate the genetic properties of the most aggressive cell types in breast cancer tumours and target the “seeds” of metastasis. To fulfill these aims, Dr Merino will use world-leading technology to label thousands of individual cells in samples from patients. She will then be able to study their biology before, during and after treatment. This strategy will allow comparison between the genetic properties of the cell with their tendency to metastasise, or develop drug resistance. |
